Launch Date
03/15/2021
Credit Amount
0.00 Expired
Credit Expires
03/15/2022
Excessive daytime sleepiness (EDS) is a primary feature of obstructive sleep apnea (OSA) and narcolepsy. Patients with EDS experience a significantly poorer quality of life (QoL) compared to those without, but despite its debilitating impact, EDS often goes undetected and underrated. It is critical that clinicians recognize the impact EDS has on their patients in order to inform optimal treatment decision-making.
This CMEO Journal Club activity is the first in a three-part series that focuses on the presentation of EDS and evidence-based measures to assess its impact on QoL so that clinicians might better educate patients on the significance of detecting and treating EDS.
At the end of this CME/CE activity, participants should be able to increase their knowledge of the clinical and QoL implications of EDS to educate patients about the significance of detection and treatment.
Supported by an educational grant from Jazz Pharmaceuticals, Inc.
Sleep specialists, pulmonologists, PCPs, PAs, NPs, nurses, pharmacists
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Bogan reports that he receives grants from Axsome Therapeutics, Inc.; Eisai Inc.; Flamel Technologies; Fresca Medical, Inc.; Harmony Biosciences, LLC; Idorsia Pharmaceuticals; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Philips; Suven Life Sciences; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He is on the speakers bureau for Eisai Inc.; Harmony Biosciences, LLC; and Jazz Pharmaceuticals, Inc.
Dr. Weaver reports that she is on the advisory board for Jazz Pharmaceuticals, Inc. She receives other financial support from Functional Outcomes of Sleep Questionnaire (FOSQ) Instrument Licensing Agreement: Bayer AG; Cook Medical; Evidation Health, Inc.; Jazz Pharmaceuticals, Inc.; LivaNova; Nyxoah; Philips Resphonics; ResMed; ResMed Germany; RWS; Stratevi; Veerily LIfe Sciences; and WCG MedAvante-ProPhase, Inc.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.
Evan Luberger (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.
NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-21-103-H01-P